인간 인슐린 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of human insulin Market

The global human insulin market was valued at USD 20.22 billion in 2025 and is projected to grow to USD 20.79 billion in 2026, reaching USD 26.93 billion by 2034, exhibiting a CAGR of 3.29% during the forecast period. North America dominated the market in 2025 with a 45.57% share, driven by high diabetes prevalence, strong healthcare infrastructure, and the presence of major pharmaceutical companies.

Insulin is a critical hormone responsible for regulating blood glucose levels. It is essential for managing diabetes, a chronic disease characterized by high blood sugar levels. Type 1 diabetes occurs when the pancreas produces little or no insulin, while Type 2 diabetes arises when the body becomes resistant to insulin. According to global estimates, over 537 million people are living with diabetes, and this number is expected to rise significantly in the coming years, boosting demand for insulin therapies.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the human insulin market, leading to a 5.5% decline in 2020. Reduced diabetes testing, limited hospital visits, and healthcare focus shifting toward COVID-19 management led to decreased insulin demand. However, the market recovered in 2021 due to resumed healthcare services, improved supply chains, and new product launches. Major companies such as Novo Nordisk A/S and Sanofi reported revenue recovery, reflecting improved market conditions.

Market Trends

A key trend shaping the market is the growing adoption of insulin analogues. These advanced formulations mimic natural insulin more closely and offer better glycemic control, faster action, and reduced risk of hypoglycemia. Long-acting insulin analogues such as insulin glargine and insulin detemir are increasingly preferred due to their stability and predictability.

Additionally, the introduction of biosimilar and affordable insulin products is improving accessibility, particularly in emerging markets. The expansion of retail and online pharmacy channels is also enhancing product availability.

Market Growth Drivers

The primary driver of market growth is the rising prevalence of diabetes, fueled by sedentary lifestyles, obesity, and unhealthy dietary habits. Increasing awareness and early diagnosis are further boosting insulin adoption.

Another important factor is the launch of innovative insulin products. Pharmaceutical companies are investing heavily in research and development to introduce new formulations, including rapid-acting and long-acting insulin. For instance, Eli Lilly and Company introduced advanced insulin therapies to improve glycemic control. Ongoing research into oral insulin delivery systems is also expected to revolutionize diabetes treatment in the future.

Restraining Factors

Despite growth opportunities, the market faces challenges due to the lack of reimbursement policies in many developing countries. High out-of-pocket expenses limit access to insulin therapy. Additionally, a high rate of undiagnosed diabetes cases, particularly in low-income regions, restricts market expansion.

Market Segmentation

By Type:

The analogue insulin segment dominates, accounting for 71.63% share in 2026, due to its superior efficacy and safety profile compared to traditional insulin.

By Diabetes Type:

The Type 1 diabetes segment leads with 62.81% share in 2026, as patients require daily insulin administration for survival. Type 2 diabetes is also growing steadily due to increasing global prevalence.

By Distribution Channel:

Retail and online pharmacies dominate, contributing 92.22% share in 2026, driven by the entry of major players such as Walmart and Amazon offering affordable insulin products and convenient access.

Regional Insights

• North America: Valued at USD 9.22 billion in 2025 and projected strong growth, with the U.S. market reaching USD 8.65 billion in 2026. High healthcare spending and diabetes prevalence drive demand.
• Europe: Recorded USD 4.2 billion in 2025 and USD 4.31 billion in 2026, supported by product innovation and strong healthcare systems.
• Asia Pacific: Accounted for USD 4.25 billion in 2025 and USD 4.41 billion in 2026, driven by rising diabetes cases in China, India, and Japan.
• Latin America: Generated USD 1.54 billion in 2025 and USD 1.59 billion in 2026, showing moderate growth.
• Middle East & Africa: Valued at USD 1.02 billion in 2025 and USD 1.04 billion in 2026, with growth constrained by limited healthcare access.

Key Companies and Industry Developments

The market is highly competitive, with leading players including:

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Biocon

Recent developments include partnerships, biosimilar launches, and pricing strategies to improve accessibility. In 2023, Novo Nordisk partnered with Aspen Pharmacare to expand insulin production in Africa, while biosimilar approvals continue to enhance market competition.

Conclusion

The global human insulin market is expected to grow steadily from USD 20.22 billion in 2025 to USD 26.93 billion by 2034, driven by the increasing prevalence of diabetes and continuous advancements in insulin therapies. While challenges such as limited reimbursement and undiagnosed cases persist, expanding access to affordable insulin and innovation in drug delivery systems will support long-term growth. North America will remain dominant, while emerging regions present significant growth opportunities as healthcare access improves worldwide.

Segmentation By Type

• Analogue Insulin
  • Long-acting
  • Fast-acting
  • Premix
• Traditional Human Insulin
  • Long-acting
  • Short-acting
  • Fast-acting
  • Premix

By Diabetes Type

• Diabetes Type 1
• Diabetes Type 2

By Distribution Channel

• Hospital Pharmacies
• Retail & Online Pharmacies

By Geography

• North America (By Type, By Diabetes Type, By Distribution Channel, and By Country)
  • U.S. (By Diabetes Type)
  • Canada (By Diabetes Type)
• Europe (By Type, By Diabetes Type, By Distribution Channel, and By Country)
  • U.K. (By Diabetes Type)
  • Germany (By Diabetes Type)
  • France (By Diabetes Type)
  • Italy (By Diabetes Type)
  • Spain (By Diabetes Type)
  • Scandinavia (By Diabetes Type)
  • Rest of Europe (By Diabetes Type)
• Asia Pacific (By Type, By Diabetes Type, By Distribution Channel, and By Country)
  • China (By Diabetes Type)
  • Japan (By Diabetes Type)
  • India (By Diabetes Type)
  • Australia (By Diabetes Type)
  • Southeast Asia (By Diabetes Type)
  • Rest of Asia Pacific (By Diabetes Type)
• Latin America (By Type, By Diabetes Type, By Distribution Channel, and By Country)
  • Brazil (By Diabetes Type)
  • Mexico (By Diabetes Type)
  • Rest of Latin America (By Diabetes Type)
• Middle East & Africa (By Type, By Diabetes Type, By Distribution Channel, and By Country)
  • GCC (By Diabetes Type)
  • South Africa (By Diabetes Type)
• Rest of Middle East & Africa (By Diabetes Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Pipeline Analysis, By Key Players
• 4.2. Pricing Analysis, By Key Countries, 2025
• 4.3. Prevalence of Diabetes, By Key Countries, 2025
• 4.4. Brand Analysis - By Key Countries
• 4.5. Key Market Strategies, By Key Players
• 4.6. Overview of Regulatory Scenario - For Key Countries/Regions
• 4.7. Impact of COVID-19 on the Market

5. Global Human Insulin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Analogue Insulin
    • 5.1.1.1. Long-acting
    • 5.1.1.2. Fast-acting
    • 5.1.1.3. Premix
  • 5.1.2. Traditional Human Insulin
    • 5.1.2.1. Long-acting
    • 5.1.2.2. Short-acting
    • 5.1.2.3. Fast-acting
    • 5.1.2.4. Premix
• 5.2. Market Analysis, Insights and Forecast - By Diabetes Type
  • 5.2.1. Diabetes Type 1
  • 5.2.2. Diabetes Type 2
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail & Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East and Africa

6. North America Human Insulin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Analogue Insulin
    • 6.1.1.1. Long-acting
    • 6.1.1.2. Fast-acting
    • 6.1.1.3. Premix
  • 6.1.2. Traditional Human Insulin
    • 6.1.2.1. Long-acting
    • 6.1.2.2. Short-acting
    • 6.1.2.3. Fast-acting
    • 6.1.2.4. Premix
• 6.2. Market Analysis, Insights and Forecast - By Diabetes Type
  • 6.2.1. Diabetes Type 1
  • 6.2.2. Diabetes Type 2
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail & Online Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Diabetes Type
  • 6.4.2. Canada
    • 6.4.2.1. By Diabetes Type

7. Europe Human Insulin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Analogue Insulin
    • 7.1.1.1. Long-acting
    • 7.1.1.2. Fast-acting
    • 7.1.1.3. Premix
  • 7.1.2. Traditional Human Insulin
    • 7.1.2.1. Long-acting
    • 7.1.2.2. Short-acting
    • 7.1.2.3. Fast-acting
    • 7.1.2.4. Premix
• 7.2. Market Analysis, Insights and Forecast - By Diabetes Type
  • 7.2.1. Diabetes Type 1
  • 7.2.2. Diabetes Type 2
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail & Online Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
    • 7.4.1.1. By Diabetes Type
  • 7.4.2. Germany
    • 7.4.2.1. By Diabetes Type
  • 7.4.3. France
    • 7.4.3.1. By Diabetes Type
  • 7.4.4. Italy
    • 7.4.4.1. By Diabetes Type
  • 7.4.5. Spain
    • 7.4.5.1. By Diabetes Type
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Diabetes Type
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Diabetes Type

8. Asia Pacific Human Insulin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Analogue Insulin
    • 8.1.1.1. Long-acting
    • 8.1.1.2. Fast-acting
    • 8.1.1.3. Premix
  • 8.1.2. Traditional Human Insulin
    • 8.1.2.1. Long-acting
    • 8.1.2.2. Short-acting
    • 8.1.2.3. Fast-acting
    • 8.1.2.4. Premix
• 8.2. Market Analysis, Insights and Forecast - By Diabetes Type
  • 8.2.1. Diabetes Type 1
  • 8.2.2. Diabetes Type 2
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail & Online Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. China
    • 8.4.1.1. By Diabetes Type
  • 8.4.2. Japan
    • 8.4.2.1. By Diabetes Type
  • 8.4.3. India
    • 8.4.3.1. By Diabetes Type
  • 8.4.4. Australia
    • 8.4.4.1. By Diabetes Type
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Diabetes Type
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Diabetes Type

9. Latin America Human Insulin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Analogue Insulin
    • 9.1.1.1. Long-acting
    • 9.1.1.2. Fast-acting
    • 9.1.1.3. Premix
  • 9.1.2. Traditional Human Insulin
    • 9.1.2.1. Long-acting
    • 9.1.2.2. Short-acting
    • 9.1.2.3. Fast-acting
    • 9.1.2.4. Premix
• 9.2. Market Analysis, Insights and Forecast - By Diabetes Type
  • 9.2.1. Diabetes Type 1
  • 9.2.2. Diabetes Type 2
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail & Online Pharmacies
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Diabetes Type
  • 9.4.2. Mexico
    • 9.4.2.1. By Diabetes Type
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Diabetes Type

10. Middle East & Africa Human Insulin Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Analogue Insulin
    • 10.1.1.1. Long-acting
    • 10.1.1.2. Fast-acting
    • 10.1.1.3. Premix
  • 10.1.2. Traditional Human Insulin
    • 10.1.2.1. Long-acting
    • 10.1.2.2. Short-acting
    • 10.1.2.3. Fast-acting
    • 10.1.2.4. Premix
• 10.2. Market Analysis, Insights and Forecast - By Diabetes Type
  • 10.2.1. Diabetes Type 1
  • 10.2.2. Diabetes Type 2
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail & Online Pharmacies
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
    • 10.4.1.1. By Diabetes Type
  • 10.4.2. South Africa
    • 10.4.2.1. By Diabetes Type
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Diabetes Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Novo Nordisk A/S
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. Eli Lilly and Company
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Sanofi
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. BIOTON S.A.
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Gan & Lee Pharmaceuticals Co Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Biocon
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Tonghua Dongbao Pharmaceutical
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Julphar
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. Wockhardt
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)